This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2006 study in 36 healthy adults that examined whether psilocybin could produce subjective experiences classified as mystical-type and whether participants later evaluated those experiences as personally and spiritually meaningful. Participants were carefully selected people with continuing involvement in religious or spiritual activities.
The study did not test religious claims or supernatural facts. It was a psychopharmacology study measuring characteristics of experience defined by questionnaires and the meanings and evaluations participants later assigned to them. An observation that an experience held deep meaning for a person is clearly distinct from proof that its content was a fact about the external world.
Study design
The study principally used a double-blind crossover design, comparing psilocybin with the active control methylphenidate in separate sessions. The sequence of conditions was balanced for 30 participants, while 6 were assigned a special sequence intended to support blinding. Preparation before sessions, continuous interpersonal support from trained monitors, and a structured environment were provided.
In addition to acute questionnaires and behavioral observation, ratings were collected from participants and community observers approximately 2 months later. Measures covered mystical experience, mood, behavioral change, personal meaning, spiritual significance, and related areas.
Content
The research asked whether psilocybin could produce more than perceptual changes, including experiences accompanied by scale items involving unity, altered senses of time and space, ineffability, positive mood, and sacredness. These were research-defined subjective measures and do not represent every culture or religion.
Setting and support were not incidental conditions; they were important parts of the research intervention. Because anxiety and fear could arise, preparation and reassuring interpersonal responses during sessions were built into the study.
Results
More participants met criteria on the mystical-experience scale in the psilocybin condition than with the active control. At 2 months, many rated the experience as one of the events in their lives with particularly high personal meaning and spiritual significance and reported positive changes in attitudes and behavior. Community-observer ratings also corresponded with some positive changes.
Some participants, however, experienced strong acute fear or anxiety. A positive average evaluation does not mean every experience was comfortable or safe. Self-reports are influenced by participants’ values and expectations.
Limitations
The sample was small and selected for healthy people interested in spiritual activities. Findings cannot be generalized to the general population, people with psychiatric illness, or different cultural backgrounds. Unblinding from distinctive effects, expectations, relationships with researchers, and questionnaire framing may have influenced results.
Follow-up was primarily 2 months and did not establish long-term benefits or harms. Community observers may also have learned participants’ allocation or expectations. Strength of subjective meaning is not proof of therapeutic efficacy or truth.
Safety
The study used careful exclusion, preparation, and monitoring. Acute fear, anxiety, and confusion nevertheless occurred. Risk changes with psychotic or manic vulnerability, cardiovascular status, medication, and environment.
This page does not guide ingestion or methods for obtaining mystical experiences. The spiritual value of an experience can be respected as the participant’s subjective perspective without conflating it with medical or external proof.
Source and rights
Original source: Griffiths RR, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–283. DOI: 10.1007/s00213-006-0457-5.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes study design, subjective assessments, results, safety, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.